Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections James PhillipsSeptember 28, 2021
Revelation Biosciences a Life Sci. Co. Developing Therapeutics & Diag. for Respiratory Viral Infections Including COVID-19 to Become Publicly Traded through a Merger with Petra Acquisition Inc James PhillipsAugust 30, 2021
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection James PhillipsMay 5, 2021
Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference James PhillipsFebruary 11, 2021
Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx‑99 James PhillipsFebruary 3, 2021
Revelation Biosciences Inc. Announces Closing of $4.4 Million in Series A-1 Financing James PhillipsFebruary 1, 2021
Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors James PhillipsJanuary 11, 2021
Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing James PhillipsJanuary 5, 2021
Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx‑99, an Experimental Treatment for Respiratory Viral Infection, Including COVID‑19 James PhillipsNovember 16, 2020
Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19 James PhillipsOctober 7, 2020
Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19 James PhillipsOctober 1, 2020
